STOCK TITAN

MAIA Biotechnology (NASDAQ: MAIA) director details trust and UTMA share changes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MAIA Biotechnology director Stan Smith reported indirect ownership changes in the company’s common stock. On September 19, 2022, The Stan V. Smith Trust Dated 1993, associated with him, purchased 2,700 shares of MAIA common stock at $3.6884 per share, bringing that trust’s reported indirect holdings to 1,424,178 shares.

On May 1, 2024, 20,000 shares previously held in the Stan V Smith CUST Gage Quentin Smith IL UNIF TRNS MIN Act account were transferred at $0 to The Stan V. Smith Trust Dated 1993, increasing that trust’s reported indirect holdings to 1,444,178 shares. Three additional IL Uniform Transfers to Minors Act accounts for family members each hold 4,580 shares, where Smith reports indirect beneficial ownership but disclaims it except to the extent of his pecuniary interest.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Smith Stan

(Last) (First) (Middle)
444 WEST LAKE STREET, SUITE 1700

(Street)
CHICAGO IL 60606

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/19/2022
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/19/2022 P 2,700 A $3.6884 1,424,178 I See Footnote(1)
Common Stock 05/01/2024 G 20,000(2) A $0 1,444,178 I See Footnote(1)
Common Stock 4,580 I See footnote(3)
Common Stock 4,580 I See footnote(4)
Common Stock 4,580 I See footnote(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
2. These securities were beneficially owned by Mr. Smith through the Stan V Smith CUST Gage Quentin Smith IL UNIF TRNS MIN Act account. On May 1, 2024, the shares were transferred to The Stan V. Smith Trust Dated 1993.
3. These securities are beneficially owned by Mr. Smith through the Blake Sarai Teitei Smith IL Unif Trns Min Act. They are beneficially owned by Mr. Smith's family member. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
4. These securities are beneficially owned by Mr. Smith through the Gage Quentin Smith IL Unif Trns Min Act. They are beneficially owned by Mr. Smith's family member. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
5. These securities are beneficially owned by Mr. Smith through the Travis Deo Zai Zai Smith IL Unif Trns Min Act. They are beneficially owned by Mr. Smith's family member. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
/s/ Stan V. Smith 01/12/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did MAIA (MAIA) report for director Stan Smith?

MAIA disclosed that director Stan Smith reported indirect ownership changes in its common stock, including a 2,700-share purchase on September 19, 2022 and a 20,000-share transfer on May 1, 2024 involving trusts and custodial accounts associated with him.

How many MAIA shares did the Stan V. Smith Trust hold after the reported transactions?

After the September 19, 2022 purchase, The Stan V. Smith Trust Dated 1993 was reported as indirectly holding 1,424,178 MAIA shares. Following the May 1, 2024 transfer of 20,000 shares into the trust, its reported indirect holdings increased to 1,444,178 shares.

What MAIA share transaction occurred on May 1, 2024 for Stan Smith’s related accounts?

On May 1, 2024, 20,000 MAIA common shares that had been beneficially owned through the Stan V Smith CUST Gage Quentin Smith IL UNIF TRNS MIN Act account were transferred at $0 to The Stan V. Smith Trust Dated 1993, changing how those shares are indirectly held.

What MAIA share purchase did the Stan V. Smith Trust report on September 19, 2022?

On September 19, 2022, The Stan V. Smith Trust Dated 1993, associated with director Stan Smith, purchased 2,700 MAIA common shares at a price of $3.6884 per share, reported as an indirect purchase.

How many MAIA shares are held in family IL Uniform Transfers to Minors Act accounts related to Stan Smith?

Three IL Uniform Transfers to Minors Act accounts for Smith’s family members—Blake Sarai Teitei Smith, Gage Quentin Smith, and Travis Deo Zai Zai Smith—each are reported as holding 4,580 MAIA common shares. Smith reports indirect beneficial ownership but disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Did the Form 4 for MAIA report any derivative securities for Stan Smith?

No derivative securities are listed in the provided Table II; it shows no derivative positions acquired, disposed of, or beneficially owned for director Stan Smith in this filing.

MAIA Biotechnology Inc.

NYSE:MAIA

MAIA Rankings

MAIA Latest News

MAIA Latest SEC Filings

MAIA Stock Data

57.40M
29.68M
21.43%
6.93%
1.98%
Biotechnology
Pharmaceutical Preparations
Link
United States
CHICAGO